{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-136687","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.973302+00:00","generated_at":"2026-06-02T02:18:40.442338+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Galera Q1 net loss narrows to $4.4M; ceases clinical development, explores strategic alternatives","bullets":["Net loss of $4.4M ($0.08/sh) vs $17.7M ($0.50/sh) in Q1 2023; R&D expenses fell to $1.5M.","Cash and equivalents $13.5M as of March 31, 2024; expected to fund operations into Q3 2025.","Company ceased all clinical trial activity and suspended clinical development of avasopasem and rucosopasem.","Board adopted stockholder rights agreement on May 3, 2024 in response to recent stock accumulations.","Evaluating strategic alternatives with Stifel; options may include mergers, asset sales, or dissolution."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-136687","json":"https://secwatch.observer/filing/0001193125-24-136687.json","markdown":"https://secwatch.observer/filing/0001193125-24-136687.md","text":"https://secwatch.observer/filing/0001193125-24-136687.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524136687/0001193125-24-136687-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524136687/d802127d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:18:40.442338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f9cb4abbcd4730bf8744cb84059dfc9e29ad7c9","claim":"Galera Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $(4.4) million, or $(0.08) per share, EPS $(0.08) per share.","evidence_excerpt":"Galera reported a net loss of $(4.4) million, or $(0.08) per share, for the first quarter of 2024, compared to a net loss of $(17.7) million, or $(0.50) per share, for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524136687/0001193125-24-136687-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$(4.4) million, or $(0.08) per share"},{"label":"EPS","value":"$(0.08) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}